Latest News - Ohr Pharmaceutical

Monday, April 10, 2017 | Clinical Trials, Ohr Pharmaceutical

Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet AMD

Ohr Pharmaceutical announced that it plans to amend the ongoing clinical trial investigating Squalamine in wet age-related macular degeneration (MAKO Study) to enable efficacy analyses by the end of c…

Read the full story

Monday, July 13, 2015 | Ohr Pharmaceutical

Ohr Pharmaceutical Announces Positive Results of a Phase 2 Clinical Study for OHR-102 in Retinal Vein Occlusion

Ohr Pharmaceutical announced positive final results from a phase 2 investigator-sponsored clinical trial of OHR-102 (0.2% Squalamine lactate ophthalmic solution) in patients with macular edema seconda…

Read the full story

Thursday, May 07, 2015 | Clinical Trials, Ohr Pharmaceutical

Ohr Pharmaceutical Presents Data From OHR-102 Phase 2 IMPACT Study in Wet AMD

Ohr Pharmaceutical presented the results from the phase 2 IMPACT study evaluating OHR-102 (0.2% squalamine lactate ophthalmic solution) combination therapy for the treatment of the wet age-related mac…

Read the full story

Friday, March 27, 2015 | Clinical Trials, Retina, Ohr Pharmaceutical

Ohr Pharmaceutical Announces Final Topline Data From OHR-102 Phase 2 IMPACT Study in Wet AMD

Ohr Pharmaceutical announced the topline results from the exploratory phase 2 IMPACT study evaluating OHR-102 (0.2% squalamine lactate ophthalmic solution) combination therapy for the treatment of the…

Read the full story

Monday, March 02, 2015 | Clinical Trials, Ohr Pharmaceutical

Ohr Pharmaceutical Announces Additional Positive Anatomic Data From the OHR-102 IMPACT Study Interim Analysis Presented at Annual Macula Society Meeting

Ohr Pharmaceutical announced the presentation of new data from the IMPACT study interim analysis at the 38th Annual Macula Society Meeting, which took place February 25-28, in Scottsdale, Arizona. The…

Read the full story